Status:
COMPLETED
To Evaluate 24-hr Glucose After OD vs BD AZD1656
Lead Sponsor:
AstraZeneca
Conditions:
Type II Diabetes
Eligibility:
All Genders
30-75 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to compare the 24-hour glucose profiles in diabetic patients treated with metformin following once daily and twice daily oral dosing
Eligibility Criteria
Inclusion
- type II diabetes patients, female with non child-bearing potential
- Type 2 Diabetes Mellitus (T2DM) diagnosis confirmed by C-peptide \>0.3nmol/L and no Glutamic acid decarboxylase (GAD) antibodies at enrolment (screening)
- Treatment with metformin as single therapy for T2DM for at least 30 days prior to enrolment and the metformin dose must have been unchanged during this period
Exclusion
- History of ischemic heart disease, symptomatic heart failure, stroke, transitory ischemic attack or symptomatic peripheral vascular disease
- Any clinically significant abnormality identified on physical examination, laboratory test or ECG, which in the judgement of investigator would compromise the subject's safety or successful participation in the clinical study
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2009
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00819884
Start Date
January 1 2009
End Date
May 1 2009
Last Update
May 7 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
San Antonio, Texas, United States